Long-term treatment of the hyperkinetic heart syndrome with propranolol

Guazzi, Maurizio D.; Polese, A; Magrini, Fabio; Fiorentini, Cesare; Mt, Olivari

doi:10.1097/00000441-197511000-00007

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with previous experience with beta-blocking treatment of such a syndrome [13][14][15][16][17][18][19][20][21][22][23][24][25], bisoprolol showed a better effect with respect to diazepam in reducing somatic aspects, particularly the cardiovascular symptoms, such as tachycardia, palpitations, and atypical chest pain. Bisoprolol also demonstrated the ability to improve the psychic profile of anxiety, confirming the possibility that the control of autonomically mediated symptoms may favorably affect the mental state, as previously suggested by some authors [21,22].…”

Section: Discussionsupporting

confidence: 90%

“…In conclusion, bisoprolol was as effective as diazepam in the treatment of cardiac neurosis, but with a more pronounced effect on somatic symptoms related to the beta-adrenergic-mediated hyperdynamic state, which confirms previous observations with other beta blockers, both betal-selective and nonselective [13][14][15][16][17][18][19][20][21][22][23][24][25][28][29][30]. As a result of several reports in the literature, the presence of betal-selectivity, ISA, and lipophilicity do not appear to substantially affect the neuropsychiatric use of beta blockers [18,[28][29][30]41,42].…”

Section: Hamilton Rating Scalessupporting

confidence: 87%

“…There is thus a strong rationale for the use of beta-adrenergic blocking drugs in the treatment of cardiac neurosis. Several studies have demonstrated that beta blockers are as effective as benzodiazepines or even more effective in improving cardiovascular symptoms [13][14][15][16][17][18][19][20][21][22][23][24][25]. As these symptoms can represent an aggravating mechanism in the anxious state, beta blockers can interrupt such a vicious circle (cardiovascular symptoms ---) anxiety ---) cardiovascular symptoms), leading to an improvement in mental symptoms as well.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis

Fogari

Zoppi

Corradi

et al. 1992

Cardiovasc Drug Ther

View full text Add to dashboard Cite

In order to compare the beta blockers bisoprolol and diazepam in the treatment of cardiac neurosis, 40 patients (16 males and 24 females, mean age: 39 +/- 11 years) were examined in a double-blind, crossover study. Following a 4-week placebo period, patients were randomized to receive either bisoprolol 10 mg daily or diazepam 5 mg twice daily for 4 weeks. After a second 4-week washout period on placebo, patients were switched to the alternative regimen for a further 4 weeks. At the end of the placebo periods and during each phase of treatment, the following parameters were evaluated: somatic symptoms by self-assessment questionnaire, anxiety state by Hamilton rating scale, reaction time to both acoustic and visual stimuli, blood pressure, and heart rate. Both treatments were effective in reducing somatic symptoms of cardiac neurosis, but bisoprolol was significantly more effective than diazepam (p less than 0.01). On the contrary, diazepam was superior to bisoprolol in improving the Hamilton scale related to psychic symptoms. Only diazepam prolonged reaction times. Both treatments were well tolerated; however, 12 patients complained of drowsiness and nine of sedation under diazepam. In conclusion, bisoprolol appeared to be as effective as diazepam in the treatment of cardiac neurosis, but with better effects on somatic symptoms and without affecting patients' psychomotor performance.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Hamilton Rating Scalessupporting

confidence: 87%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis

Fogari

Zoppi

Corradi

et al. 1992

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

Training mit initialer β-Rezeptorenblockade als Therapie von juvenilen Grenzwerthypertonikern

Hörtnagl

Baumgartner

Wiedermann

et al. 1985

Training Und Sport Zur Prävention Und Rehabilitation in Der Technisierten Umwelt / Training and Sport for Prevention and Rehabi

View full text Add to dashboard Cite

Alinidine and propranolol treatment of hyperkinetic heart syndrome

et al. 1987

View full text Add to dashboard Cite

A hyperkinetic heart syndrome has been diagnosed in 10 patients by clinical investigation and right-heart catheterization at rest and during exercise. Subsequently, the patients received 3 X 40 mg alinidine, and 2 X 40 mg propranolol and placebo, each for 2 weeks in a double-blind crossover study. Heart rate at rest (P less than 0.05) and during exercise (P less than 0.001) decreased significantly under alinidine and propranolol to the same extent (control, 83/170; alinidine, 68/146; propranolol, 73/139; placebo, 83/162 beats per min). Lower limb flow at rest and after exercise, measured by plethysmography, as well as left-ventricular fractional shortening and mean velocity of circumferential fiber shortening, measured by echocardiography, decreased insignificantly. Sedation and a dry mouth occurred in six patients under alinidine, while fatigue and cold hands and/or feet were reported by five patients under propranolol. Thus, alinidine may be used as an alternative to beta-blocking in the treatment of the hyperkinetic heart syndrome.

show abstract

Long-term treatment of the hyperkinetic heart syndrome with propranolol

Cited by 7 publications

References 0 publications

Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis

Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis

Training mit initialer β-Rezeptorenblockade als Therapie von juvenilen Grenzwerthypertonikern

Alinidine and propranolol treatment of hyperkinetic heart syndrome

Contact Info

Product

Resources

About